UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Inflammatory Bowel Disease in Latin America: A Systematic Review

Calderón, M; Minckas, N; Nuñez, S; Ciapponi, A; (2018) Inflammatory Bowel Disease in Latin America: A Systematic Review. Value in Health Regional Issues , 17 pp. 126-134. 10.1016/j.vhri.2018.03.010. Green open access

[thumbnail of Minckas_IBD paper .pdf]
Preview
Text
Minckas_IBD paper .pdf - Accepted Version

Download (293kB) | Preview
[thumbnail of Minckas_IBD Tables.pdf]
Preview
Text
Minckas_IBD Tables.pdf - Accepted Version

Download (232kB) | Preview
[thumbnail of Minckas_IBD Figure 1 .pdf]
Preview
Text
Minckas_IBD Figure 1 .pdf - Accepted Version

Download (77kB) | Preview

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) is the name given to two inflammatory diseases of the colon and/or small intestine: Crohn disease (CD) and ulcerative colitis (UC). There is no information summarizing the complete body of evidence about IBD in developing regions, including Latin America. OBJECTIVES: To estimate the burden of IBD in Latin America. METHODS: We conducted a systematic review searching published and unpublished studies on major international and regional databases from January 2000 to September 2015. Outcomes considered were incidence, prevalence, mortality, hospitalization attributable, treatment patterns, comparative effectiveness, patient-reported outcomes, and adherence to treatment. Pairs of reviewers independently selected, extracted, and assessed the risk of bias of the studies. Discrepancies were solved by consensus. RESULTS: We retrieved 3445 references, finally including 25 studies. Only 19% of the observational studies had a low risk of bias for participant selection and 60% were based on registries. The incidence ranged from 0.74 to 6.76/100,000 person-years for UC and from 0.24 to 3.5/100,000 person-years for CD. The prevalence rate ranged from 0.99 to 44.3/100,000 inhabitants for UC and 0.24 to 16.7/100,000 inhabitants for CD. Mortality rates ranged from 0.60 to 1.02 for UC and from 0.23 to 0.40 for CD. Patient-reported outcomes showed a decrease in quality of life associated with depression and anxiety and correlated with the time of diagnosis. The most frequently used medication in the studies was mesalazine. CONCLUSIONS: The burden of IBD in Latin America seems to be important, but there is a considerable gap of high-quality evidence in the region.

Type: Article
Title: Inflammatory Bowel Disease in Latin America: A Systematic Review
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.vhri.2018.03.010
Publisher version: http://doi.org/10.1016/j.vhri.2018.03.010
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Crohn disease, Latin America and the Caribbean, burden of disease, epidemiology, inflammatory bowel disease, ulcerative colitis
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10053064
Downloads since deposit
17,556Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item